Last update 21 Mar 2024
HNRNPD
heterogeneous nuclear ribonucleoprotein D
Last update 21 Mar 2024
Basic Info
Synonyms AU-rich element RNA-binding protein 1, AUF1, heterogeneous nuclear ribonucleoprotein D + [4] |
Introduction Binds with high affinity to RNA molecules that contain AU-rich elements (AREs) found within the 3'-UTR of many proto-oncogenes and cytokine mRNAs. Also binds to double- and single-stranded DNA sequences in a specific manner and functions a transcription factor. Each of the RNA-binding domains specifically can bind solely to a single-stranded non-monotonous 5'-UUAG-3' sequence and also weaker to the single-stranded 5'-TTAGGG-3' telomeric DNA repeat. Binds RNA oligonucleotides with 5'-UUAGGG-3' repeats more tightly than the telomeric single-stranded DNA 5'-TTAGGG-3' repeats. Binding of RRM1 to DNA inhibits the formation of DNA quadruplex structure which may play a role in telomere elongation. May be involved in translationally coupled mRNA turnover. Implicated with other RNA-binding proteins in the cytoplasmic deadenylation/translational and decay interplay of the FOS mRNA mediated by the major coding-region determinant of instability (mCRD) domain. May play a role in the regulation of the rhythmic expression of circadian clock core genes. Directly binds to the 3'UTR of CRY1 mRNA and induces CRY1 rhythmic translation. May also be involved in the regulation of PER2 translation. |
Related
100 Clinical Results associated with HNRNPD
Login to view more data
100 Translational Medicine associated with HNRNPD
Login to view more data
0 Patents (Medical) associated with HNRNPD
Login to view more data
449
Literatures (Medical) associated with HNRNPD20 Feb 2024·Molecular carcinogenesis
RhoGDIβ inhibition via miR-200c/AUF1/SOX2/miR-137 axis contributed to lncRNA MEG3 downregulation-mediated malignant transformation of human bronchial epithelial cells.
Article
Author: Yichao Yang ; Zhongxian Tian ; Lijiong He ; Hao Meng ; Xiaomin Xie ; Ziyi Yang ; Xinxing Wang ; Yunping Zhao ; Chuanshu Huang
Nickel pollution is a recognized factor contributing to lung cancer. Understanding the molecular mechanisms of its carcinogenic effects is crucial for lung cancer prevention and treatment. Our previous research identified the downregulation of a long noncoding RNA, maternally expressed gene 3 (MEG3), as a key factor in transforming human bronchial epithelial cells (HBECs) into malignant cells following nickel exposure. In our study, we found that deletion of MEG3 also reduced the expression of RhoGDIβ. Notably, artificially increasing RhoGDIβ levels counteracted the malignant transformation caused by MEG3 deletion in HBECs. This indicates that the reduction in RhoGDIβ contributes to the transformation of HBECs due to MEG3 deletion. Further exploration revealed that MEG3 downregulation led to enhanced c-Jun activity, which in turn promoted miR-200c transcription. High levels of miR-200c subsequently increased the translation of AUF1 protein, stabilizing SOX2 messenger RNA (mRNA). This stabilization affected the regulation of miR-137, SP-1 protein translation, and the suppression of RhoGDIβ mRNA transcription and protein expression, leading to cell transformation. Our study underscores the co-regulation of RhoGDIβ expression by long noncoding RNA MEG3, multiple microRNAs (miR-200c and miR-137), and RNA-regulated transcription factors (c-Jun, SOX2, and SP1). This intricate network of molecular events sheds light on the nature of lung tumorigenesis. These novel findings pave the way for developing targeted strategies for the prevention and treatment of human lung cancer based on the MEG3/RhoGDIβ pathway.
16 Feb 2024·Science advances
Enterovirus evolution reveals the mechanism of an RNA-targeted antiviral and determinants of viral replication.
Article
Author: Jesse Davila-Calderon ; Mei-Ling Li ; Srinivasa R Penumutchu ; Christina Haddad ; Linzy Malcolm ; Josephine King ; Amanda E Hargrove ; Gary Brewer ; Blanton S Tolbert
Selective pressures on viruses provide opportunities to establish target site specificity and mechanisms of antivirals. Enterovirus (EV)-A71 with resistant mutations in the stem loop (SL) II internal ribosome entry site (IRES) (SLIIresist) were selected at low doses of the antiviral dimethylamiloride (DMA)-135. The EV-A71 mutants were resistant to DMA-135 at concentrations that inhibit replication of wild-type virus. EV-A71 IRES structures harboring resistant mutations induced efficient expression of Luciferase messenger RNA in the presence of noncytotoxic doses of DMA-135. Nuclear magnetic resonance indicates that the mutations change the structure of SLII at the binding site of DMA-135 and at the surface recognized by the host protein AU-rich element/poly(U)-binding/degradation factor 1 (AUF1). Biophysical studies of complexes formed between AUF1, DMA-135, and either SLII or SLIIresist show that DMA-135 stabilizes a ternary complex with AUF1-SLII but not AUF1-SLIIresist. This work demonstrates how viral evolution elucidates the (DMA-135)-RNA binding site specificity in cells and provides insights into the viral pathways inhibited by the antiviral.
05 Feb 2024·International journal of biological macromolecules
Human RNA-binding protein HNRNPD interacts with and regulates the repair of deoxyribouridine in DNA.
Article
Author: Ziyu Wang ; Minghui Qu ; Sijia Chang ; Xiaoxia Dai ; Changjun You
Deoxyribouridine (dU) is an abnormal nucleoside in DNA and plays vital roles in multiple biological and physiological processes. Here, we conducted a mass spectrometry-based screen for dU-binding proteins and found that the heterogeneous nuclear ribonucleoprotein D (HNRNPD) could preferentially bind to dU-containing DNA. We also discovered that HNRNPD engages in the 5-Fluorouracil (5FU)-induced DNA damage response and can modulate the repair of dU in DNA in vitro and in human cells. Moreover, using a shuttle vector- and next-generation sequencing-based method, we unveiled the crucial role of HNRNPD in promoting the replicative bypass of dU in human cells. Taken together, these findings suggested that HNRNPD is a novel dU-bearing DNA-binding protein capable of regulating the removal of dU in DNA, and provided new insights into the molecular mechanisms of dU-associated diseases.
1
News (Medical) associated with HNRNPD02 May 2023
REGENXBIO Announces Presentations at the American Society of Gene & Cell Therapy 26th Annual Meeting
ROCKVILLE, Md., May 2, 2023 /PRNewswire/ -- REGENXBIO Inc. (Nasdaq: RGNX) today announced presentations at the American Society of Gene & Cell Therapy (ASGCT) 26th Annual Meeting, taking place in Los Angeles, California from May 16 through 20, 2023. The presentations highlight the Company's end-to-end capabilities across clinical development and research and early development.
The presentations will be presented as follows:
Oral Presentations:
Abstract Title: AUF1 Gene Therapy for Duchenne Muscular Dystrophy Increases Durable Endogenous Utrophin Expression, Muscle Regeneration and Muscle Function Performance in Pre-clinical Animal Studies (abstract #135)
Presenter: Dounia Abbadi, Postdoctoral Fellow, NYU Langone Medical Center
Session: Gene Tx Approaches for Muscle & Skeletal Diseases
Date/Time: Thursday, May 18, 2023, 2:38-2:55 p.m. PST
Abstract Title: Mechanistic Evaluation of Liver-specific Transgene Repression from AAV Vectors in Non-Human Primates and Minipigs (abstract #249)
Presenter: Zhuo Wang, Ph.D., Scientist II, Research & Early Development at REGENXBIO
Session: AAV Vector Genome Biology & Engineering II
Date/Time: Friday, May 19 3:45-4:00 p.m. PST
Poster Presentations:
Abstract Title: RGX-121 gene therapy for the treatment of neuronopathic mucopolysaccharidosis type II (MPS II): Interim analysis of data from the first in human study (abstract #807)
Presenter: Paul Harmatz, M.D., Professor in Residence at University of California, San Francisco
Session: Wednesday Poster Session
Date/Time: Wednesday, May 17, 2023 12:00-2:00 p.m. PST & 5:30-7:00 p.m. PST
Abstract Title: In Silico Prediction and In Vivo Testing of Promoters Targeting GABAergic Inhibitory Neurons (abstract #385)
Presenter: Robert Duba-Kiss, Ph.D. Candidate, Pharmacology/Neuroscience at University of Toronto University of Toronto
Session: Wednesday Poster Session
Date/Time: Wednesday, May 17, 2023 12:00-2:00 p.m. PST & 5:30-7:00 p.m. PST
Abstract Title: Development of AAV-Expressed C5 Inhibitor to Locally Suppress Complement Pathway Activation in the Eye as a Potential Treatment for Dry Age-related Macular Degeneration (abstract #364)
Presenter: Wei-Hua Lee, Ph.D., Senior Scientist, Research & Early Development at REGENXBIO
Session: Wednesday Poster Session
Date/Time: Wednesday, May 17, 2023 12:00-2:00 p.m. PST & 5:30-7:00 p.m. PST
Abstract Title: Addition of a Protein Domain from the Dystrophin C-Terminus Improves Functional and Biochemical Properties of AAV-Encoded Microdystrophin (abstract #668)
Presenter: Steven Foltz, Ph.D., Senior Scientist, Research & Early Development at REGENXBIO
Session: Wednesday Poster Session
Date/Time: Wednesday, May 17, 2023 12:00-2:00 p.m. PST & 5:30-7:00 p.m. PST
Abstract Title: Optimization of AAV-DARPin Fusions to Redirect Capsid Tropism (abstract #447)
Presenter: Elad Firnberg, Ph.D., Senior Scientist, Research & Early Development at REGENXBIO
Session: Wednesday Poster Session
Date/Time: Wednesday, May 17, 2023 12:00-2:00 p.m. PST & 5:30-7:00 p.m. PST
Abstract Title: RGX-111 gene therapy for the treatment of severe mucopolysaccharidosis type I (MPS I): Interim analysis of data from the first in human study (abstract #932)
Presenter: Laura Pisani-Betancourt, MD, MBA, FACMG, Senior Medical Director, Clinical Development Lead at REGENXBIO
Session: Thursday Poster Session
Date/Time: Thursday May 18, 2023 12:00-2:00 p.m. PST & 5:30-7:00 p.m. PST
Abstract Title: Local Delivery of Vectorized Therapeutics Targeting a Pro-inflammatory Cytokine Effectively Reduces Disease Severity in a Mouse Model of Non-Infectious Uveitis (abstract #860)
Presenter: Jessica Gumerson, Ph.D., Scientist II, Research & Early Development at REGENXBIO
Session: Thursday Poster Session
Date/Time: Thursday May 18, 2023 12:00-2:00 p.m. PST & 5:30-7:00 p.m. PST
Abstract Title: High Resolution Biodistribution Analysis Following Suprachoroidal Administration of a Pool of AAV3B, AAV8, and AAV9 Vectors to Non-Human Primates Reveals Spatial and Cell-Based Tropism Differences (abstract #876)
Presenter: April R. Giles, Ph.D., Senior Scientist, Research & Early Development at REGENXBIO
Session: Thursday Poster Session
Date/Time: Thursday, May 18, 2023 12:00-2:00 p.m. PST & 5:30-7:00 p.m. PST
Abstract Title: Utility of Cryofluorescence Tomography (CFT) as an Unbiased Method to Describe AAV Biodistribution (abstract #1278)
Presenter: Samantha A. Yost, Ph.D., Senior Scientist, Research & Early Development at REGENXBIO
Session: Friday Poster Session
Date/Time: Friday, May 19, 2023 12:00-2:00 p.m. PST & 5:30-7:00 p.m. PST
Abstract Title: Development of a Self-Complementary AAV.U7snRNA Vector for Efficient Dystrophin Exon 53 Skipping (abstract #1565)
Presenter: Randolph Qian, Ph.D., Scientist II, Research & Early Development at REGENXBIO
Session: Friday Poster Session
Date/Time: Friday, May 19, 2023 12:00-2:00 p.m. PST & 5:30-7:00 p.m. PST
Abstract Title: Kinetic Analyses Reveal Very Early CpG-specific Antagonism to AAV-Mediated Transgene Expression: Implications for TLR9 Stimulatory Effects Prior to Effector T Cell Activation Following Gene Transfer (abstract #1487)
Presenter: Justin D. Glenn, Ph.D., Senior Scientist, Research & Early Development at REGENXBIO
Session: Friday Poster Session
Date/Time: Friday, May 19, 2023 12:00-2:00 p.m. PST & 5:30-7:00 p.m. PST
NAV® Technology Licensees:
Abstract Title: AAV Vector DNA Carrying Two Concatenated miRNA Stem-Loops is Highly Homogenous and Stable in GLP-Grade AAV Product
Presenter: Chenxia HE, Ph.D., Director of Gene Therapy at uniQure, in collaboration with REGENXBIO
Session: AAV Vectors – Product Development Manufacturing: Analytics & Stability Studies
Date/Time: Thursday, May 18, 2023, 1:45-2:00 p.m. PST
Abstract Title: Preclinical Proof-of-Concept of AMT-260, a Novel AAV9-Dual microRNA-Based Vector Targeting GRIK2 for the Treatment of Temporal Lobe Epilepsy (abstract #1159)
Presenter: Nick Pearson, Head of Toxicology & Translational Safety at uniQure, in collaboration with REGENXBIO
Session: Thursday Poster Session
Date/Time: Thursday, May 18, 2023 12:00-2:00 p.m. PST & 5:30-7:00 p.m. PST
About REGENXBIO Inc.
REGENXBIO is a leading clinical-stage biotechnology company seeking to improve lives through the curative potential of gene therapy. REGENXBIO's NAV Technology Platform, a proprietary adeno-associated virus (AAV) gene delivery platform, consists of exclusive rights to more than 100 novel AAV vectors, including AAV7, AAV8 and AAV9. REGENXBIO and its third-party NAV Technology Platform Licensees are applying the NAV Technology Platform in the development of a broad pipeline of candidates, including late-stage and commercial programs, in multiple therapeutic areas. REGENXBIO is committed to a "5x'25" strategy to progress five AAV Therapeutics from our internal pipeline and licensed programs into pivotal-stage or commercial products by 2025.
Contacts:
Dana Cormack
Corporate Communications
[email protected]
Investors:
Chris Brinzey
ICR Westwicke
339-970-2843
[email protected]
SOURCE REGENXBIO Inc.
Gene TherapyClinical Study
Analysis
Perform a panoramic analysis of this field.
login
or
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free